Donald James Annino, Jr., D.M.D., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 27 | 2024 | 2868 | 1.760 |
Why?
|
| Neck Dissection | 7 | 2011 | 200 | 1.050 |
Why?
|
| Facial Transplantation | 5 | 2021 | 220 | 1.030 |
Why?
|
| Carcinoma, Squamous Cell | 18 | 2024 | 4004 | 0.910 |
Why?
|
| Osteoradionecrosis | 1 | 2022 | 51 | 0.830 |
Why?
|
| Free Tissue Flaps | 2 | 2024 | 321 | 0.790 |
Why?
|
| Esophageal Stenosis | 4 | 2013 | 195 | 0.630 |
Why?
|
| Radiotherapy, Intensity-Modulated | 8 | 2022 | 806 | 0.600 |
Why?
|
| Paranasal Sinuses | 1 | 2020 | 265 | 0.590 |
Why?
|
| Endoscopy | 4 | 2020 | 1838 | 0.580 |
Why?
|
| Enophthalmos | 2 | 2008 | 37 | 0.560 |
Why?
|
| Maxillary Sinusitis | 2 | 2008 | 41 | 0.550 |
Why?
|
| Rhinoplasty | 1 | 2020 | 236 | 0.550 |
Why?
|
| Maxillary Sinus | 2 | 2008 | 181 | 0.500 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2022 | 1005 | 0.480 |
Why?
|
| Orbital Diseases | 2 | 2008 | 184 | 0.480 |
Why?
|
| Dilatation | 3 | 2013 | 303 | 0.460 |
Why?
|
| Neoplasms, Unknown Primary | 3 | 2022 | 100 | 0.420 |
Why?
|
| Mouth Neoplasms | 4 | 2024 | 591 | 0.400 |
Why?
|
| Deglutition Disorders | 4 | 2011 | 617 | 0.350 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2020 | 300 | 0.320 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2008 | 121 | 0.280 |
Why?
|
| Radiation Injuries | 2 | 2019 | 1180 | 0.280 |
Why?
|
| Relative Biological Effectiveness | 1 | 2008 | 321 | 0.280 |
Why?
|
| Oropharyngeal Neoplasms | 3 | 2022 | 488 | 0.260 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 550 | 0.240 |
Why?
|
| Facial Neuralgia | 1 | 2003 | 10 | 0.230 |
Why?
|
| Laryngectomy | 2 | 2003 | 244 | 0.230 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2005 | 140 | 0.230 |
Why?
|
| Toothache | 1 | 2003 | 31 | 0.230 |
Why?
|
| Lipectomy | 1 | 2005 | 111 | 0.230 |
Why?
|
| Pharyngectomy | 1 | 2003 | 44 | 0.220 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2003 | 112 | 0.220 |
Why?
|
| Larynx | 1 | 2008 | 491 | 0.220 |
Why?
|
| Facial Injuries | 3 | 2014 | 186 | 0.220 |
Why?
|
| Ultrasonic Therapy | 1 | 2005 | 215 | 0.220 |
Why?
|
| Mitomycin | 1 | 2003 | 259 | 0.210 |
Why?
|
| HIV Protease Inhibitors | 1 | 2005 | 434 | 0.210 |
Why?
|
| Pharyngeal Diseases | 1 | 2003 | 136 | 0.200 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2011 | 1774 | 0.190 |
Why?
|
| Face | 2 | 2020 | 1011 | 0.190 |
Why?
|
| Nasolacrimal Duct | 1 | 2022 | 78 | 0.190 |
Why?
|
| Middle Aged | 41 | 2024 | 217019 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2024 | 9207 | 0.180 |
Why?
|
| Graft Rejection | 4 | 2021 | 4219 | 0.180 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 2789 | 0.180 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 1594 | 0.180 |
Why?
|
| Combined Modality Therapy | 13 | 2013 | 8538 | 0.180 |
Why?
|
| Nasal Mucosa | 2 | 2020 | 411 | 0.170 |
Why?
|
| Retrospective Studies | 23 | 2024 | 79127 | 0.160 |
Why?
|
| Skin Pigmentation | 1 | 2021 | 275 | 0.160 |
Why?
|
| Male | 49 | 2024 | 354881 | 0.160 |
Why?
|
| Radiotherapy Dosage | 6 | 2022 | 2906 | 0.150 |
Why?
|
| Microsurgery | 1 | 2003 | 778 | 0.150 |
Why?
|
| Mouth Mucosa | 1 | 2020 | 428 | 0.150 |
Why?
|
| Esophagoscopy | 2 | 2013 | 391 | 0.140 |
Why?
|
| Triage | 1 | 2024 | 977 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2011 | 3489 | 0.140 |
Why?
|
| Qualitative Research | 2 | 2024 | 2885 | 0.140 |
Why?
|
| Postoperative Complications | 5 | 2021 | 15437 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2014 | 20348 | 0.140 |
Why?
|
| Aged | 32 | 2024 | 166562 | 0.140 |
Why?
|
| Precancerous Conditions | 1 | 2024 | 969 | 0.140 |
Why?
|
| Transplantation, Homologous | 3 | 2021 | 4637 | 0.140 |
Why?
|
| Female | 41 | 2024 | 386053 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2021 | 11586 | 0.130 |
Why?
|
| Surgical Flaps | 2 | 2003 | 1657 | 0.130 |
Why?
|
| Adult | 28 | 2024 | 216913 | 0.130 |
Why?
|
| Humans | 59 | 2024 | 752341 | 0.120 |
Why?
|
| Treatment Outcome | 17 | 2021 | 64245 | 0.120 |
Why?
|
| Ear, External | 1 | 1995 | 164 | 0.120 |
Why?
|
| Zenker Diverticulum | 1 | 2014 | 25 | 0.120 |
Why?
|
| Epistaxis | 1 | 2014 | 111 | 0.110 |
Why?
|
| Surgical Stapling | 1 | 2014 | 96 | 0.110 |
Why?
|
| Reoperation | 2 | 2021 | 4256 | 0.110 |
Why?
|
| Sphenoid Bone | 1 | 2014 | 177 | 0.110 |
Why?
|
| Solitary Fibrous Tumor, Pleural | 1 | 2013 | 25 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2005 | 3474 | 0.110 |
Why?
|
| Paranasal Sinus Neoplasms | 2 | 2007 | 240 | 0.110 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 58300 | 0.100 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 887 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2024 | 3560 | 0.100 |
Why?
|
| Laryngeal Neoplasms | 3 | 2011 | 513 | 0.090 |
Why?
|
| Orbital Neoplasms | 1 | 2013 | 225 | 0.090 |
Why?
|
| Neck | 2 | 2005 | 724 | 0.090 |
Why?
|
| Syndrome | 2 | 2008 | 3271 | 0.090 |
Why?
|
| Vincristine | 1 | 1992 | 1028 | 0.090 |
Why?
|
| Deglutition | 1 | 2011 | 200 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 3117 | 0.090 |
Why?
|
| Airway Obstruction | 1 | 2014 | 655 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2019 | 23783 | 0.080 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2009 | 94 | 0.080 |
Why?
|
| Vocal Cord Paralysis | 1 | 1992 | 269 | 0.080 |
Why?
|
| Recovery of Function | 3 | 2014 | 2921 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1686 | 0.080 |
Why?
|
| Pleural Neoplasms | 1 | 2013 | 625 | 0.080 |
Why?
|
| Neoplasm Staging | 5 | 2024 | 11064 | 0.070 |
Why?
|
| Lymphatic Metastasis | 3 | 2010 | 2924 | 0.070 |
Why?
|
| Cancer Care Facilities | 3 | 2019 | 419 | 0.070 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2006 | 26 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2008 | 872 | 0.070 |
Why?
|
| Antineoplastic Agents | 4 | 2023 | 13553 | 0.070 |
Why?
|
| Hospitalization | 2 | 2020 | 10627 | 0.060 |
Why?
|
| Models, Economic | 1 | 2009 | 714 | 0.060 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 386 | 0.060 |
Why?
|
| Respiration Disorders | 1 | 2008 | 369 | 0.060 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 6781 | 0.060 |
Why?
|
| Survival Analysis | 5 | 2019 | 10177 | 0.060 |
Why?
|
| Diplopia | 1 | 2005 | 214 | 0.060 |
Why?
|
| Leukoplakia, Oral | 1 | 2024 | 74 | 0.060 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2003 | 113 | 0.060 |
Why?
|
| Neurosurgical Procedures | 1 | 2014 | 2023 | 0.060 |
Why?
|
| Organ Specificity | 1 | 2008 | 1952 | 0.050 |
Why?
|
| Eating | 1 | 2010 | 1537 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 1 | 2010 | 1051 | 0.050 |
Why?
|
| Frontal Sinus | 1 | 2002 | 51 | 0.050 |
Why?
|
| Orbit | 1 | 2005 | 444 | 0.050 |
Why?
|
| Dermoid Cyst | 1 | 2002 | 91 | 0.050 |
Why?
|
| Administration, Topical | 1 | 2003 | 694 | 0.050 |
Why?
|
| Cohort Studies | 5 | 2024 | 40984 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 12455 | 0.050 |
Why?
|
| Parotid Gland | 1 | 2022 | 174 | 0.050 |
Why?
|
| Survival Rate | 3 | 2010 | 12746 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2010 | 6360 | 0.050 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 3755 | 0.050 |
Why?
|
| Nose Neoplasms | 1 | 2002 | 248 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2003 | 1099 | 0.040 |
Why?
|
| Organs at Risk | 1 | 2022 | 362 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2005 | 9158 | 0.040 |
Why?
|
| Prognosis | 4 | 2024 | 29327 | 0.040 |
Why?
|
| Skull Base Neoplasms | 1 | 2002 | 270 | 0.040 |
Why?
|
| Range of Motion, Articular | 1 | 2005 | 1572 | 0.040 |
Why?
|
| Patient Selection | 1 | 2010 | 4238 | 0.040 |
Why?
|
| Radiation Dosage | 2 | 2022 | 1969 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 4495 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2009 | 871 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 11266 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2024 | 2620 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 4274 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 52 | 0.030 |
Why?
|
| Quality of Life | 4 | 2024 | 13153 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2022 | 1102 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2019 | 654 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2024 | 6058 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2021 | 1265 | 0.030 |
Why?
|
| Embryonic and Fetal Development | 1 | 1995 | 421 | 0.030 |
Why?
|
| Ear Canal | 1 | 1995 | 146 | 0.030 |
Why?
|
| Length of Stay | 2 | 2021 | 6372 | 0.030 |
Why?
|
| Laryngismus | 1 | 1994 | 29 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 15130 | 0.030 |
Why?
|
| Vocal Cords | 2 | 2000 | 522 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2016 | 452 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 6501 | 0.030 |
Why?
|
| Thermosensing | 1 | 2013 | 55 | 0.030 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 1640 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 6413 | 0.030 |
Why?
|
| Laryngeal Muscles | 1 | 1994 | 107 | 0.030 |
Why?
|
| Follow-Up Studies | 5 | 2013 | 39079 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2022 | 1676 | 0.030 |
Why?
|
| Acute Disease | 1 | 2003 | 7211 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2016 | 499 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2021 | 8443 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 694 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 20843 | 0.030 |
Why?
|
| Nasal Cavity | 1 | 2014 | 304 | 0.030 |
Why?
|
| Botulinum Toxins | 1 | 1994 | 189 | 0.030 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2005 | 1849 | 0.030 |
Why?
|
| Aneurysm, False | 1 | 2014 | 258 | 0.020 |
Why?
|
| Respiratory Sounds | 2 | 1994 | 695 | 0.020 |
Why?
|
| Hemostasis | 1 | 2014 | 458 | 0.020 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2011 | 49 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2020 | 1422 | 0.020 |
Why?
|
| Touch | 1 | 2013 | 310 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2013 | 651 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 15676 | 0.020 |
Why?
|
| Xerostomia | 1 | 2010 | 94 | 0.020 |
Why?
|
| Voice Disorders | 1 | 1994 | 283 | 0.020 |
Why?
|
| Health Personnel | 1 | 2023 | 3266 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2020 | 2483 | 0.020 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2013 | 355 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 5281 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 2174 | 0.020 |
Why?
|
| Melanoma | 1 | 2007 | 5620 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 600 | 0.020 |
Why?
|
| Gastrostomy | 1 | 2011 | 316 | 0.020 |
Why?
|
| Cerebral Angiography | 1 | 2014 | 1252 | 0.020 |
Why?
|
| DNA | 1 | 2022 | 7215 | 0.020 |
Why?
|
| Surgical Wound Infection | 2 | 2011 | 1499 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2013 | 1828 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2021 | 3412 | 0.020 |
Why?
|
| Boston | 2 | 2011 | 9236 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2024 | 4601 | 0.020 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2007 | 59 | 0.020 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2007 | 101 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 10797 | 0.020 |
Why?
|
| Respiration | 1 | 1994 | 1646 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 1992 | 703 | 0.020 |
Why?
|
| Erythrocyte Transfusion | 1 | 2011 | 555 | 0.020 |
Why?
|
| Carboplatin | 1 | 2009 | 788 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1391 | 0.020 |
Why?
|
| Taxoids | 1 | 2009 | 664 | 0.020 |
Why?
|
| Markov Chains | 1 | 2009 | 968 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 6306 | 0.020 |
Why?
|
| Risk Factors | 2 | 2014 | 73412 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2007 | 460 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 2895 | 0.020 |
Why?
|
| Young Adult | 3 | 2017 | 57629 | 0.020 |
Why?
|
| Embolization, Therapeutic | 1 | 2014 | 1393 | 0.020 |
Why?
|
| Base Sequence | 1 | 2016 | 12432 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2009 | 1606 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2007 | 632 | 0.010 |
Why?
|
| Adenoma | 1 | 2014 | 2141 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 3599 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2019 | 3797 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3600 | 0.010 |
Why?
|
| Cisplatin | 1 | 2009 | 1643 | 0.010 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2009 | 1708 | 0.010 |
Why?
|
| Cerebrospinal Fluid Otorrhea | 1 | 2002 | 15 | 0.010 |
Why?
|
| Diet | 2 | 2014 | 7949 | 0.010 |
Why?
|
| Cranial Nerve Injuries | 1 | 2002 | 25 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 2 | 2009 | 9101 | 0.010 |
Why?
|
| Incidence | 2 | 2014 | 21158 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2009 | 1699 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2008 | 902 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 8422 | 0.010 |
Why?
|
| Recurrence | 1 | 2014 | 8420 | 0.010 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 1 | 2002 | 87 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 25535 | 0.010 |
Why?
|
| Adolescent | 2 | 2023 | 86765 | 0.010 |
Why?
|
| Endovascular Procedures | 1 | 2014 | 2058 | 0.010 |
Why?
|
| Travel | 1 | 2006 | 782 | 0.010 |
Why?
|
| Age of Onset | 1 | 2007 | 3288 | 0.010 |
Why?
|
| Meningitis | 1 | 2002 | 217 | 0.010 |
Why?
|
| Dura Mater | 1 | 2002 | 287 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2020 | 53807 | 0.010 |
Why?
|
| Thyroid Cartilage | 1 | 2000 | 43 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 9355 | 0.010 |
Why?
|
| Surgical Mesh | 1 | 2002 | 302 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2009 | 2680 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2014 | 4830 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 9551 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2013 | 4877 | 0.010 |
Why?
|
| Craniotomy | 1 | 2002 | 740 | 0.010 |
Why?
|
| Bone Transplantation | 1 | 2002 | 913 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2006 | 2020 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2009 | 5481 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2009 | 6170 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 2002 | 1272 | 0.010 |
Why?
|
| Gene Expression | 1 | 2007 | 7580 | 0.010 |
Why?
|
| Hypertension | 1 | 2014 | 8496 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 14586 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 11007 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 8892 | 0.010 |
Why?
|
| Laser Therapy | 1 | 2000 | 1092 | 0.010 |
Why?
|
| Disease Progression | 1 | 2009 | 13402 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2013 | 35916 | 0.010 |
Why?
|
| Radiography | 1 | 2002 | 6964 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 8931 | 0.010 |
Why?
|
| Infant | 1 | 1992 | 35673 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1992 | 41659 | 0.010 |
Why?
|
| Time Factors | 1 | 1994 | 39854 | 0.000 |
Why?
|